NDRA · ENDRA Life Sciences Inc.
$4.60
+0.03 (+0.55%)
At close · Aug 7
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company has not established an ongoing source of revenue sufficient to cover its operating costs and to allow it to continue as a going concern and will require additional financing to fund its future planned operations, including research and development and commercialization of its products. These matters raise substantial doubt about the Company's ability to continue as going concern.”View the 10-Q filed May 15, 2026
Market Cap
$5.84M
Shares
1.27M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-07-10 | 2,780 | $5.49 | $15,262 |
| 2026-07-06 | 73 | $4.72 | $345 |
| 2026-07-02 | 2 | $5.04 | $10 |
| 2026-06-29 | 771 | $4.99 | $3,847 |
| 2026-06-26 | 2,345 | $4.30 | $10,084 |
| 2026-06-25 | 2,394 | $6.19 | $14,819 |
| 2026-06-24 | 303 | $5.31 | $1,609 |
| 2026-06-23 | 868 | $5.18 | $4,496 |
| 2026-06-22 | 826 | $4.76 | $3,932 |
| 2026-06-18 | 1,666 | $5.01 | $8,347 |
| 2026-06-17 | 782 | $4.62 | $3,613 |
| 2026-06-16 | 850 | $4.85 | $4,123 |
| 2026-06-12 | 1,708 | $4.44 | $7,584 |
| 2026-06-05 | 8 | $4.77 | $38 |
| 2026-05-29 | 265 | $5.52 | $1,463 |
| 2026-05-22 | 292 | $5.35 | $1,562 |
| 2026-05-19 | 202 | $5.41 | $1,093 |
| 2026-05-15 | 428 | $5.90 | $2,525 |
| 2026-05-13 | 1,096 | $5.79 | $6,346 |
Showing 1–19 of 19 settlements